Hearing aid company Demant's business has been booming in the first half of 2021 – so much so that the group now books an upward adjustment of its full-year guidance.
Demant now banks on organic growth of 26-30 percent against the prior spread of 24-28 percent, also dialing up on its expectations for annual earnings before interest and taxes from DKK 3-3.3bn (USD 470-520m) to DKK 3.15-3.45bn, the company informs in its H1 interim report.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.